Practice Setting Requirements. In accordance with M.G.L. c. 112, § 24B½, subsection (c), collaborative drug therapy management may be performed in the following settings by pharmacists meeting the requirements of 247 CMR 16.02(1) and authorized by a supervising physician pursuant to a current collaborative practice agreement:
Practice Setting Requirements. In accordance with M.G.L. c. 112, § 24B½, subsection (c), collaborative drug therapy management may be performed in the following settings by pharmacists meeting the requirements of 247 CMR 16.02(1) and authorized by a supervising physician pursuant to a current collaborative practice agreement: Hospitals licensed pursuant to M.G.L. c. 111, § 51, subject to approval by the hospital medical staff executive committee or designee; Long-term Care Facilities licensed pursuant to M.G.L. c. 111, § 71, subject to approval by the long-term care facility medical director or designee; Inpatient or Outpatient Hospice Settings licensed pursuant to M.G.L. c. 111, § 57D, subject to approval by the hospice medical director or designee; Ambulatory Care Clinics licensed pursuant to M.G.L. c. 111, § 51, with on-site supervision by an attending physician affiliated with the ambulatory clinic and an authorized pharmacist, subject to approval by the ambulatory care clinic medical staff executive committee or designee, or medical director or designee; Community Pharmacies (retail drug business settings) licensed by the Board pursuant to M.G.L. c. 112, § 39, subject to the restrictions listed below and pursuant to a current collaborative practice agreement that includes the following requirements: Patient Age. Patients must be 18 years of age or older. Vaccine Administration. Pharmacists, as authorized pursuant to a collaborative practice agreement, may administer vaccines. Patient Referral and Consent. In accordance with 243 CMR 2.12, the collaborative practice agreement must provide that the supervising physician will: provide a written referral of the patient to the authorized pharmacist; specify the primary diagnosis for the patient and any secondary diagnoses in the written referral or a subsequent referral; provide a copy of the written referral of the patient to the authorized pharmacist for CDTM services to the patient; and obtain the patient's written informed consent to the collaboration in the collaborative practice agreement and provide a copy of the consent to the patient.
